Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Schutkowski

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|November 30, 2022
Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory PropertiesPing Sun, Jing Wang, Khadija S Khan, et al.
Autophagy|February 22, 2015
SIRT5 regulation of ammonia-induced autophagy and mitophagyLucia Polletta, Enza Vernucci, Ilaria Carnevale, et al.
Nature Communications|February 13, 2015
Selective Sirt2 inhibition by ligand-induced rearrangement of the active siteTobias Rumpf, Matthias Schiedel, Berin Karaman, et al.
Journal of Medicinal Chemistry|May 29, 2026
Macrophage-Centric Phenotypic Screening Identifies Tetrazolone-Based HDAC6 Inhibitors That Reprogram the Tumor Immune Microenvironment and Improve Immune Checkpoint BlockadeNithya Gajendran, Manasa Suresh, Sebastian J Marquez R, et al.
International Journal of Molecular Sciences|January 11, 2022
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic ActivityHany S Ibrahim, Mohamed Abdelsalam, Yanira Zeyn, et al.
Nature Communications|December 20, 2017
A 1-phytase type III effector interferes with plant hormone signalingDoreen Blüher, Debabrata Laha, Sabine Thieme, et al.
Cell Reports|April 3, 2013
The SH2 domain interaction landscapeMichele Tinti, Lars Kiemer, Stefano Costa, et al.
Bioorganic Chemistry|April 19, 2025
Unlocking the potential of novel tetrahydro-β-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluationNoreen Hemida, Dalia S El-Gamil, Ahmed K ElHady, et al.
RSC Medicinal Chemistry|April 21, 2025
Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancerAya Fathy, Amro Allam, Ahmed K ElHady, et al.
Molecular Biology and Evolution|June 17, 2026
Functional Divergence and Structural Changes of class IV Histone Deacetylases (HDACs) Across the Tree of LifeZora Nováková, Pavla Bartošová-Sojková, Julia Kudláčová, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|November 30, 2022
Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory PropertiesPing Sun, Jing Wang, Khadija S Khan, et al.
Autophagy|February 22, 2015
SIRT5 regulation of ammonia-induced autophagy and mitophagyLucia Polletta, Enza Vernucci, Ilaria Carnevale, et al.
Nature Communications|February 13, 2015
Selective Sirt2 inhibition by ligand-induced rearrangement of the active siteTobias Rumpf, Matthias Schiedel, Berin Karaman, et al.
Journal of Medicinal Chemistry|May 29, 2026
Macrophage-Centric Phenotypic Screening Identifies Tetrazolone-Based HDAC6 Inhibitors That Reprogram the Tumor Immune Microenvironment and Improve Immune Checkpoint BlockadeNithya Gajendran, Manasa Suresh, Sebastian J Marquez R, et al.
International Journal of Molecular Sciences|January 11, 2022
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic ActivityHany S Ibrahim, Mohamed Abdelsalam, Yanira Zeyn, et al.
Nature Communications|December 20, 2017
A 1-phytase type III effector interferes with plant hormone signalingDoreen Blüher, Debabrata Laha, Sabine Thieme, et al.
Cell Reports|April 3, 2013
The SH2 domain interaction landscapeMichele Tinti, Lars Kiemer, Stefano Costa, et al.
Bioorganic Chemistry|April 19, 2025
Unlocking the potential of novel tetrahydro-β-carboline-based HDAC6 inhibitors for colorectal cancer therapy: Design, synthesis and biological evaluationNoreen Hemida, Dalia S El-Gamil, Ahmed K ElHady, et al.
RSC Medicinal Chemistry|April 21, 2025
Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancerAya Fathy, Amro Allam, Ahmed K ElHady, et al.
Molecular Biology and Evolution|June 17, 2026
Functional Divergence and Structural Changes of class IV Histone Deacetylases (HDACs) Across the Tree of LifeZora Nováková, Pavla Bartošová-Sojková, Julia Kudláčová, et al.
Pageof 11